学术周报 · IF≥10

消化内科领域文献阅读汇编

2026年第42周 (2026-10-17) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
17
临床研究
3
基础研究
14
IF≥20
8
IF 10-20
9
子领域
8
期刊种类
16
数据日期
2026-10-17

★本周 Top 10 高影响力文献

#论文期刊IF
1Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism.NatureIF 56.1
2In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanopa...Nature biotechnologyIF 44.5
3Cardiovascular Complications of Chronic Liver Disease.CirculationIF 41.3
4Myofibroblast Derived Transglutaminase 2 Activity is Upregulated in Stricturing Crohn's Disease and ...GastroenterologyIF 29.7
5HtpG-High-Expressing Escherichia coli Promotes Fibrosis in Chronic Pancreatitis.GastroenterologyIF 29.7
6Zbtb44-mediated transcriptional repression critically regulates colonic inflammation.Nature immunologyIF 26.5
7Pleiotropic roles of microbial bile acid metabolism in intestinal health and diseases.Cell host & microbeIF 23.2
8The Brain-Gut-Microbiome Axis: Exploring the Link Between Depression and Irritable Bowel Syndrome.Annual review of physiologyIF 20.3
9Extensive genomic diversity in Desulfovibrio reveals species-specific functional traits associated w...Nature communicationsIF 18.1
10Intestinal T-cell migration: unraveling mechanisms and therapeutic implications.Journal of advanced researchIF 17.1

Ŧ期刊分布统计

期刊篇数IF
Gastroenterology2IF 29.7
Drugs1IF 14.7
Carbohydrate polymers1IF 13.2
Biosensors & bioelectronics1IF 11.8
Cell death and differentiation1IF 13.6
Nature1IF 56.1
Pharmacological research1IF 12.2
Cell host & microbe1IF 23.2
Annual review of physiology1IF 20.3
ACS sensors1IF 10.9

1炎症性肠病/IBD (10篇)

临床研究 (1篇)

Drugs IF 14.7 2026-10-15 PMID: 42879081
Fatigue is one of the most common and disabling symptoms experienced by individuals with inflammatory bowel disease (IBD). Significant fatigue is experienced by approximately 40-80% of adults with IBD, with higher prevalence during active disease states but persisting in up to one-third of individuals who are in clinical remission. Fatigue is not solely a consequence of disease activity, but rather a unique and multifactorial manifestation of IBD. In this narrative review we synthesize evidence on the various mechanisms of fatigue in IBD, as well as pharmacological agents to address fatigue both directly or through secondary contributors including anaemia, psychiatric comorbidities, sleep disturbance, and pain. The review further situates pharmacological therapy within a holistic framework that integrates non-pharmacological approaches as part of a multidisciplinary approach to fatigue in IBD. Drug therapy has a meaningful role in this context, both when targeting disease-related inflammation and secondary contributors to fatigue. However, the evidence base for most of these approaches remains weak. It is clear that no single pharmacological agent will resolve IBD-related fatigue in isolation, but effective management should identify a patient's dominant contributors and address them systematically with both drug and nondrug intervention strategies. This framework should be delivered by a multidisciplinary team through an integrated care approach and optimally be guided by the patient's priorities and goals.
中文摘要:疲乏是炎症性肠病(IBD)患者最常见且最影响生活功能的症状之一。约40%~80%的成年IBD患者存在明显疲乏,疾病活动期患病率更高,但即使在临床缓解者中,仍有约三分之一持续存在疲乏。疲乏并非仅由疾病活动引起,而是IBD的一种独特且多因素的表现。本叙述性综述汇总了IBD疲乏多种发生机制的证据,以及针对疲乏本身或通过贫血、精神共病、睡眠障碍和疼痛等继发因素间接改善疲乏的药物。综述进一步将药物治疗置于整体管理框架中,把非药物手段纳入IBD疲乏的多学科管理。在这一框架下,药物治疗具有实际作用,既可针对疾病相关炎症,也可针对疲乏的继发因素。但多数此类措施的循证依据仍然薄弱。单一药物显然无法单独解决IBD相关疲乏,有效的管理应识别患者的主要影响因素,并以药物与非药物策略系统性地加以处理。该框架应由多学科团队通过整合照护的方式实施,并最好以患者的优先事项与目标为导向。

基础研究 (9篇)

Carbohydrate polymers IF 13.2 2026-10-15 PMID: 42692637
Weaning-induced intestinal dysfunction remains a significant challenge, characterized by microbial dysbiosis and immune suppression. However, the precise molecular mechanisms by which specific structural features of levan-fructans influence host homeostasis through microbial metabolic pathways are not fully understood. Here, a branched levan-type exopolysaccharide from Bacillus subtilis BS21 (BS21EPS), characterized by a β-(2 → 6)-D-fructofuranosyl backbone and β-(2 → 1) linkages, reduces colonic damage and systemic inflammation. Metagenomic sequencing shows that BS21EPS supplementation selectively increases Lactobacillus johnsonii 428 in the colon, which contains specialized GH32 enzymes for levan degradation. Integrative metabolomics identifies kynurenic acid (KYNA) as the primary microbial metabolite consistently increased both in vivo and in vitro, which mechanistically serves as a potent endogenous ligand for the aryl hydrocarbon receptor (AhR). In a mouse colitis model, supplementation with L. johnsonii 428 or KYNA enhances intestinal barrier function and reduces inflammation by influencing T-cell lineage decisions, especially by promoting Treg expansion while inhibiting Th17 differentiation. Notably, AhR antagonism with CH223191 abrogates these immunomodulatory effects, confirming the crucial role of the KYNA-AhR axis in maintaining immune balance. Collectively, these findings reveal a structural-functional link between dietary levans, providing a targeted nutritional strategy for managing weaning-related dysfunction and inflammatory bowel diseases.
中文摘要:断奶诱导的肠道功能障碍仍是一项重要挑战,其特征为微生物失调和免疫抑制。果聚糖类特定结构特征如何通过微生物代谢途径影响宿主稳态,其精确分子机制尚未充分明确。枯草芽孢杆菌BS21产生的分支型果聚糖类胞外多糖(BS21EPS)具有β-(2→6)-D-果呋喃糖基主链和β-(2→1)连接,可减轻结肠损伤和全身炎症。宏基因组测序显示,补充BS21EPS可选择性地增加结肠中的约氏乳杆菌428,该菌含有用于果聚糖降解的专用GH32酶。整合代谢组学鉴定出犬尿喹啉酸(KYNA)是在体内和体外均持续升高的主要微生物代谢物,其在机制上作为芳烃受体(AhR)的强效内源性配体。在小鼠结肠炎模型中,补充约氏乳杆菌428或KYNA可通过影响T细胞谱系决定来增强肠道屏障功能并减轻炎症,尤其表现为促进Treg扩增并抑制Th17分化。用CH223191拮抗AhR可消除这些免疫调节效应,证实KYNA-AhR轴在维持免疫平衡中的关键作用。这些结果共同揭示了膳食果聚糖类在结构与功能之间的联系,为管理断奶相关功能障碍和炎症性肠病提供了靶向营养策略。
Cell death and differentiation IF 13.6 2026-10-14 PMID: 42875598
Nucleotide-binding oligomerization domain containing 2 (NOD2) recognizes conserved bacterial components in the cytoplasm to initiate innate immune responses, and its mutations are closely associated with Crohn's disease (CD). Here, we discover that the NOD2 signaling is regulated by the deubiquitinase USP25. Macrophages lacking USP25 exhibit impaired NOD2 signaling and are defective in cytokine production upon stimulation with muramyl dipeptide (MDP). USP25 enhances NOD2-initiated signal transduction by increasing the expression and recruitment of X-linked inhibitor of apoptosis protein (XIAP). In mice, USP25 deficiency exacerbates intestinal inflammation induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS), whereas USP25 overexpression alleviates TNBS-induced colitis. Moreover, USP25 deficiency leads to spontaneous intestinal inflammation in aged mice. Importantly, a known single nucleotide polymorphism associated with human inflammatory bowel disease compromises USP25 expression, and lower USP25 expression is detected in patients with CD. Thus, USP25 plays a critical role in NOD2 signaling and may represent a potential therapeutic target for CD.
中文摘要:NOD2识别胞质内保守的细菌成分以启动天然免疫反应,其突变与克罗恩病密切相关。本研究发现NOD2信号受去泛素化酶USP25调控。缺乏USP25的巨噬细胞在MDP刺激下NOD2信号受损,细胞因子产生存在缺陷。USP25通过提高XIAP的表达和募集增强NOD2启动的信号转导。小鼠中USP25缺失加重TNBS诱导的肠道炎症,而USP25过表达减轻TNBS诱导的结肠炎。USP25缺失还可导致老年小鼠发生自发性肠道炎症。与人类炎症性肠病相关的一个已知单核苷酸多态性会削弱USP25表达,克罗恩病患者中也可检测到较低的USP25表达。USP25在NOD2信号中起关键作用,可能成为克罗恩病的潜在治疗靶点。
Nature IF 56.1 2026-10-14 PMID: 42875499
Interleukin-10 (IL-10) is a central anti-inflammatory cytokine that suppresses immune responses in myeloid cells but can also activate T cells, limiting its therapeutic use in chronic inflammatory diseases owing to narrow efficacy windows and dose-limiting toxicities1-5. Here we show that myeloid and T cells differ in their dependence on JAK-family kinase pairing for IL-10 signalling and function. We took advantage of this differential kinase dependence to engineer a tetravalent nanobody-based myeloid-selective IL-10 receptor agonist (msIL-10R agonist) that fully recapitulates IL-10's potent suppression of monocytes, macrophages and dendritic cells while avoiding stimulation of T cells. Cryo-electron microscopy structural analysis reveals a distinct receptor cross-linking geometry of the msIL-10R agonist compared with native IL-10 family cytokines. This tetravalent architecture renders signalling strictly TYK2-dependent and highly sensitive to IL-10Rα and IL-10Rβ receptor abundance, thereby conferring selective activity in myeloid cells. This msIL-10R agonist reduces inflammation in humanized mouse models of lipopolysaccharide challenge, delayed-type hypersensitivity and colitis. A humanized version exhibits IgG-like pharmacokinetics, sustained receptor occupancy and durable myeloid suppression up to 30 days without T cell activation or haematological toxicities in non-human primates. These findings establish a geometry-based strategy for achieving cell-type-selective cytokine signalling and identify the msIL-10R agonist as a therapeutic candidate for myeloid-driven inflammatory diseases, including inflammatory bowel diseases.
中文摘要:白细胞介素-10(IL-10)是核心抗炎细胞因子,可抑制髓系细胞的免疫反应,但也能激活T细胞;由于疗效窗窄和剂量限制性毒性,其在慢性炎症性疾病中的治疗应用受限。本研究发现,髓系细胞与T细胞在IL-10信号传导和功能上对JAK家族激酶配对的依赖不同。利用这种激酶依赖性差异,我们构建了基于纳米抗体的四价髓系选择性IL-10受体激动剂(msIL-10R激动剂),其可完整重现IL-10对单核细胞、巨噬细胞和树突状细胞的强效抑制作用,同时避免刺激T细胞。冷冻电镜结构分析显示,与天然IL-10家族细胞因子相比,msIL-10R激动剂具有不同的受体交联几何构型。这种四价结构使信号传导严格依赖TYK2,并对IL-10Rα和IL-10Rβ受体的丰度高度敏感,从而赋予其在髓系细胞中的选择性活性。该msIL-10R激动剂在脂多糖攻击、迟发型超敏反应和结肠炎的人源化小鼠模型中减轻炎症。人源化版本在非人灵长类中表现出类IgG药代动力学、持续受体占据以及长达30天的持久髓系抑制,且未出现T细胞激活或血液学毒性。这些结果建立了一种基于几何构型的细胞类型选择性细胞因子信号策略,并将msIL-10R激动剂确定为髓系驱动炎症性疾病(包括炎症性肠病)的治疗候选物。
Pharmacological research IF 12.2 2026-10-14 PMID: 42874825
Endoplasmic reticulum (ER) stress and mitochondrial dysfunction are key pathogenic drivers in inflammatory bowel disease (IBD). Chronic ER stress impairs epithelial barrier integrity and stimulates inflammatory pathways, causing cell death. Simultaneously, mitochondrial dysfunction results in excessive reactive oxygen species production, bioenergetic failure, and defective mitophagy, further disrupting intestinal homeostasis. Notably, these two organellar stress responses are physically and functionally linked via mitochondria-ER contacts (MERCs), which form signaling platforms-mitochondria-associated ER membranes. These platforms coordinate calcium transfer and redox signaling while integrating autophagy and the unfolded protein response (UPR). This review comprehensively summarizes the current molecular mechanisms by which ER stress and mitochondrial dysfunction aid IBD pathogenesis, emphasizing calcium homeostasis imbalance, oxidative stress, disrupted mitochondrial quality control, and autophagy-UPR integration. Furthermore, this article highlights the functional interplay between the ER and mitochondria, as well as the MERCs that structurally connect them. Additionally, it discusses emerging diagnostic biomarkers and therapeutic strategies based on these mechanisms, aiming to offer theoretical insights and novel perspectives for IBD research and clinical intervention.
中文摘要:内质网应激与线粒体功能障碍是炎症性肠病(IBD)的重要致病驱动因素。慢性内质网应激损害上皮屏障完整性并激活炎症通路,导致细胞死亡。线粒体功能障碍则引起活性氧产生过多、生物能量衰竭及线粒体自噬缺陷,进一步破坏肠道稳态。这两种细胞器应激反应通过线粒体-内质网接触(MERCs)在物理和功能上相连,形成信号平台——线粒体相关内质网膜;这些平台协调钙转运与氧化还原信号,并整合自噬与未折叠蛋白反应(UPR)。本综述系统总结内质网应激与线粒体功能障碍促进IBD发病的现有分子机制,重点涉及钙稳态失衡、氧化应激、线粒体质量控制受损以及自噬-UPR整合。文章还强调内质网与线粒体之间的功能互作,以及从结构上连接二者的MERCs。文中讨论基于这些机制的新兴诊断生物标志物和治疗策略,旨在为IBD研究与临床干预提供理论依据和新视角。
ACS sensors IF 10.9 2026-10-14 PMID: 42872713
Current treatments for inflammatory bowel disease (IBD) lack real-time inflammatory monitoring and lesion-specific drug delivery, resulting in poor efficacy and systemic toxicity. To address this, we present a smart oral capsule that operates a closed-loop "sense-decide-act" strategy entirely autonomously-sensing and drug release are driven by changes in the digestive tract environment without any external intervention. The capsule features a dual-layer shell sequentially responsive to pH and matrix metalloproteinases (MMPs), enabling colon-targeted delivery and inflammation-specific activation. An integrated multimodal sensor wirelessly tracks colonic TNF-α (>5 ng mL-1), pH (>7.0), and Na+ (>100 mM). The encapsulated budesonide nanoparticles (Bud@PEG-SS-NPs) release the drug specifically in reactive oxygen species (ROS)-rich microenvironments and show superior anti-inflammatory efficacy in both lipopolysaccharide (LPS)-induced cellular models and dextran sulfate sodium (DSS)-induced mouse colitis. In live rats, the capsule achieved on-demand drug release in response to elevated local TNF-α levels, and a single intervention significantly alleviated inflammation. This work establishes a new paradigm for personalized, adaptive IBD therapy and provides a versatile platform for closed-loop management of other gastrointestinal diseases.
中文摘要:当前炎症性肠病(IBD)治疗缺乏实时炎症监测和病灶特异性给药,导致疗效不佳和全身毒性。为此,研究者提出一种智能口服胶囊,完全自主运行闭环「感知-决策-执行」策略,感知与释药均由消化道环境变化驱动,无需外部干预。胶囊采用双层壳,依次响应pH和基质金属蛋白酶(MMPs),实现结肠靶向递送和炎症特异性激活。集成的多模态传感器可无线追踪结肠TNF-α(>5 ng mL-1)、pH(>7.0)和Na+(>100 mM)。封装的布地奈德纳米粒(Bud@PEG-SS-NPs)在富含活性氧(ROS)的微环境中特异性释放药物,在脂多糖(LPS)诱导的细胞模型和葡聚糖硫酸钠(DSS)诱导的小鼠结肠炎中均显示更优的抗炎效果。在活体大鼠中,胶囊响应局部TNF-α水平升高实现按需释药,单次干预显著减轻炎症。该工作为个性化、适应性IBD治疗建立了新范式,并为其他胃肠道疾病的闭环管理提供了通用平台。
Gastroenterology IF 29.7 2026-10-13 PMID: 42869257
Excessive accumulation of extracellular matrix (ECM) derived from human intestinal myofibroblasts (HIMF) drives the significant clinical problem of intestinal fibrosis. Fibrosis is believed to progress even in the absence of intestinal inflammation. ECM-bound transglutaminase 2 (TG2) enzyme may exert direct pro-fibrotic effects. We investigated the role of TG2 in intestinal fibrosis. TG2 expression and activity in human intestinal tissue and HIMF from strictured Crohn's disease (CDs), and controls were measured. ECM accumulation by HIMF in presence or absence of TG2 inhibitors was determined. Putative TG2 signaling pathways discovered in HIMF using bulk RNA sequencing (bulk-RNAseq) and single cell RNA sequencing (scRNAseq) were functionally validated. Role of TG2 in vivo was confirmed using inducible global knockout of TGM2 (encoding TG2) in two experimental fibrosis models. TG activity was increased in CDs compared to controls, with up to 100% activity attributable to TG2. TG activity correlated with the degree of histopathologic tissue fibrosis. HIMF were the major source of TG2, with ≥95% of HIMF TG activity being derived from TG2. Tissue distribution of TG2 in myofibroblasts was confirmed by scRNAseq analysis. Selective inhibition of TG2 activity reduced fibronectin (FN), collagen (COL)I, III and VI accumulation by HIMF. Novel TG2 signaling pathways revealed by bulk-RNAseq, were functionally validated. Inducible TGM2 knockout prevented experimental fibrosis without affecting the degree of intestinal inflammation. TG2 may be involved in inflammation-independent progression of intestinal fibrosis.
中文摘要:人肠道肌成纤维细胞(HIMF)来源的细胞外基质(ECM)过度积累是肠道纤维化这一重要临床问题的基础。纤维化被认为可在肠道炎症缺失时仍继续进展。结合于ECM的转谷氨酰胺酶2(TG2)可能具有直接促纤维化作用。我们研究了TG2在肠道纤维化中的作用。检测狭窄型克罗恩病(CDs)和对照的人肠道组织及HIMF中TG2的表达与活性。测定有无TG2抑制剂时HIMF的ECM积累。利用bulk RNA测序和单细胞RNA测序发现HIMF中可能的TG2信号通路,并进行功能验证。用两种实验性纤维化模型中的诱导性全身TGM2(编码TG2)敲除确认TG2的体内作用。CDs中TG活性较对照升高,高达100%的活性可归因于TG2。TG活性与组织病理学纤维化程度相关。HIMF是TG2的主要来源,HIMF中至少95%的TG活性来自TG2。单细胞RNA测序分析证实TG2在肌成纤维细胞中的组织分布。选择性抑制TG2活性可减少HIMF对纤连蛋白(FN)、I型、III型和VI型胶原(COL)的积累。bulk RNA测序揭示的新TG2信号通路经功能验证。诱导性TGM2敲除可阻止实验性纤维化,且不影响肠道炎症程度。TG2可能参与不依赖炎症的肠道纤维化进展。
Nature immunology IF 26.5 2026-10-12 PMID: 42864399
The regulatory mechanisms that maintain colonic immune homeostasis remain incompletely understood. Here we show that genetic deletion of Zbtb44, a previously uncharacterized member of the ZBTB transcription factor family, leads to spontaneous colitis and rectal prolapse. Zbtb44-/- T cells expressed increased IFN-γ, a pro-inflammatory cytokine strongly associated with human inflammatory bowel disease. Mechanistically, Zbtb44 undergoes SUMOylation, which facilitates its interaction with a conserved SUMO-interacting motif in T-bet, enabling binding to the IFN-γ promoter and enhancer to restrain chronic IFN-γ production. Together, these findings demonstrate that Zbtb44 is a key regulator of colonic inflammation, a role that could be exploited therapeutically.
中文摘要:维持结肠免疫稳态的调控机制仍未完全明确。本研究发现,ZBTB转录因子家族中此前功能未明的成员Zbtb44基因缺失可导致自发性结肠炎和直肠脱垂。Zbtb44-/- T细胞表达增多的IFN-γ,这是一种与人类炎症性肠病密切相关的促炎细胞因子。机制上,Zbtb44发生SUMO化,促进其与T-bet中保守的SUMO相互作用基序结合,从而结合IFN-γ启动子和增强子,限制慢性IFN-γ产生。这些结果说明Zbtb44是结肠炎症的关键调控因子,这一作用可被用于治疗开发。
Nature communications IF 18.1 2026-10-10 PMID: 42859157
Desulfovibrio spp. are associated with inflammatory diseases and human health, yet limited representative genomes and isolates hinder our understanding of their role in disease. Here, we assembled a comprehensive database of 2658 Desulfovibrio genomes across 90 diseases and 32 countries, including 24 human isolates. Genomic analyses showed extensive species diversity and revealed disease-associated functional traits, including flagellin and adaptation-associated genes (i.e., ureases). Flagellin-mediated Toll-like receptor 5 activation was species-specific and D. desulfuricans flagellin downregulated TGF-beta signalling in murine small intestinal organoids, suggesting impaired immune tolerance. Additionally, we investigated genomic capacity for hydrogen sulfide (H2S) production, a main Desulfovibrio metabolite. While health- and disease-associated Desulfovibrio spp. mainly encoded dissimilatory sulfate reduction, tetrathionate metabolism-encoding bacteria were exclusively detected in inflammatory bowel diseases, including Proteus mirabilis and Morganella morganii. Overall, our study provides a comprehensive genomic Desulfovibrio resource and identifies new links associating strain variation, functional traits and H2S-production with inflammatory diseases.
中文摘要:脱硫弧菌属(Desulfovibrio spp.)与炎症性疾病和人类健康相关,但代表性基因组和分离株有限,限制了对这类细菌在疾病中作用的认识。本研究组装了涵盖90种疾病和32个国家的2658个脱硫弧菌基因组综合数据库,其中包括24株人源分离株。基因组分析显示广泛的物种多样性,并揭示疾病相关功能特征,包括鞭毛蛋白和适应相关基因(如脲酶)。鞭毛蛋白介导的Toll样受体5激活具有物种特异性,D. desulfuricans鞭毛蛋白下调小鼠小肠类器官中的TGF-β信号,提示免疫耐受受损。研究还考察了硫化氢(H2S)产生的基因组能力,H2S是脱硫弧菌的主要代谢产物。健康相关和疾病相关脱硫弧菌主要编码异化型硫酸盐还原,而编码四硫代硫酸盐代谢的细菌仅在炎症性肠病中检出,包括奇异变形杆菌和摩根摩根菌。该研究提供了全面的脱硫弧菌基因组资源,并识别出菌株变异、功能特征和H2S产生与炎症性疾病之间的新联系。
Journal of advanced research IF 17.1 2026-10-10 PMID: 42858844
Intestinal T-cell migration links mucosal immunity with systemic immune homeostasis and contributes to immune surveillance, barrier defense, and peripheral tissue inflammation. Advances in single-cell omics, spatial analysis, and intravital imaging are reshaping our understanding of its subset specificity and tissue selectivity. This review summarizes the molecular mechanisms, microenvironmental regulation, pathological significance along the gut-organ axes, and related therapeutic strategies of intestinal T-cell migration, with a particular focus on how migratory imbalance contributes to intestinal and extraintestinal immune-mediated diseases. Intestinal T-cell migration is jointly driven by gut imprinting, S1P-S1PR-mediated egress, chemokine-guided trafficking, integrin-dependent adhesion, and cytoskeletal remodeling, and is further regulated by metabolic, epigenetic, and microbial signals. This process is highly dependent on T-cell subset and tissue context: it promotes effector T-cell recruitment and inflammatory amplification in inflammatory bowel disease, manifests as restricted antitumor T-cell infiltration in colorectal cancer, and may contribute to distant tissue injury through the gut-organ axes. Existing S1PR modulators, integrin antagonists, and chemokine-targeted strategies have demonstrated the therapeutic tractability of migratory pathways; however, pathway redundancy, tissue heterogeneity, and impairment of protective immunity continue to limit their application. Future strategies should move beyond broad suppression of migration toward subset-, tissue-, and disease stage-specific precision modulation, combined with microbiota-based interventions and biomarker-guided stratification to improve therapeutic efficacy.
中文摘要:肠道T细胞迁移把黏膜免疫与全身免疫稳态联系起来,参与免疫监视、屏障防御和外周组织炎症。单细胞组学、空间分析及活体成像的进展正在重塑人们对其亚群特异性和组织选择性的认识。本综述归纳肠道T细胞迁移的分子机制、微环境调控、沿肠-器官轴的病理意义及相关治疗策略,重点关注迁移失衡如何促成肠道及肠外免疫介导性疾病。肠道T细胞迁移由肠道印记、S1P-S1PR介导的出口、趋化因子引导的转运、整合素依赖的黏附以及细胞骨架重塑共同驱动,并进一步受代谢、表观遗传和微生物信号调控。该过程高度依赖T细胞亚群与组织背景:在炎症性肠病中促进效应T细胞募集与炎症放大,在结直肠癌中表现为抗肿瘤T细胞浸润受限,并可能经肠-器官轴参与远处组织损伤。现有的S1PR调节剂、整合素拮抗剂和趋化因子靶向策略已显示迁移通路具备治疗可操作性,但通路冗余、组织异质性及保护性免疫受损仍限制其应用。未来策略应从广谱抑制迁移转向按亚群、组织和疾病阶段实施的精准调控,并结合基于微生物群的干预与生物标志物指导的分层,以提高疗效。

2病毒性肝炎 (1篇)

基础研究 (1篇)

Biosensors & bioelectronics IF 11.8 2026-10-15 PMID: 42177864
Viral hepatitis, particularly hepatitis B (HB) and hepatitis C (HC), has remained a major global health concern for decades due to its high infectivity and the liver damage it causes, which can lead to severe long-term complications. Thus, the development of diagnostic tools that enable rapid, cost-effective, and user-friendly detection of hepatitis infections is crucial. Here, we report label-free immunosensors for the detection of HB/HC biomarkers (Hepatitis B surface antigen, HBsAg, and Hepatitis C core antigen, HCcAg) using conventional electrolyte-gated organic field effect transistors (EGOFETs) as electrical transducers by modifying the gate contact with suitable antibodies. To enhance portability and enable point-of-care (PoC) operation, the EGOFETs were subsequently integrated into a lateral flow assay architecture (LF-EGOFET), where the antibodies are immobilized within a nitrocellulose membrane in contact with a coplanar gate electrode. The devices were evaluated as PoC diagnostic tests in buffer solutions and diluted artificial saliva, demonstrating high sensitivity, selectivity, and accuracy, with limits of detection (LoD) in the femtomolar range. Notably, the LF-EGOFET platform achieves a LoD over three orders of magnitude lower than those of commercial hepatitis lateral flow assays, while avoiding the use of labels and enabling the identification of discrete concentration ranges.
中文摘要:病毒性肝炎,尤其是乙肝和丙肝,因传染性强并可造成肝损伤、进而引发严重长期并发症,数十年来一直是全球重大健康问题。开发能够快速、低成本且易用的肝炎感染诊断工具十分关键。本研究报道了无标记免疫传感器,用于检测乙肝和丙肝生物标志物,即乙肝表面抗原HBsAg和丙肝核心抗原HCcAg;该传感器以常规电解质栅控有机场效应晶体管EGOFET作为电换能器,并通过合适抗体修饰栅极接触。为提升便携性并实现即时检测操作,随后将EGOFET集成到侧向流分析架构中形成LF-EGOFET,抗体固定在硝酸纤维素膜内并与共平面栅电极接触。器件在缓冲液和稀释人工唾液中作为即时诊断测试进行评估,表现出高灵敏度、选择性和准确性,检测限达到飞摩尔范围。LF-EGOFET平台的检测限比商业肝炎侧向流检测低三个数量级以上,同时避免使用标记,并能识别离散的浓度范围。

3幽门螺杆菌/微生态 (1篇)

基础研究 (1篇)

Cell host & microbe IF 23.2 2026-10-14 PMID: 42874562
Perturbation of microbial-derived bile acid (BA) metabolism is strongly linked to the pathogenesis of intestinal diseases, including inflammatory bowel disease, enteric infections, and colorectal cancer. Recent advances in artificial intelligence-assisted pipelines have enabled the identification of BA modification reactions, which have uncovered novel targets and the mechanisms contributing to intestinal diseases. In this review, we summarize recent studies on microbial enzymatic pathways and modifications of BAs, and their roles in promoting or preventing intestinal diseases. The mechanisms altering gut microbiota populations and microbial BA metabolic landscapes that influence intestinal diseases are further examined along with how microbial-derived BAs modulate intestinal immune responses. Based on these advances, we suggest different dietary patterns that reshape the gut microbiota community and BAs to prevent intestinal diseases. We further discuss current challenges in basic and translational research on microbial BA modifications in intestinal homeostasis and propose future directions to drive progress in this field.
中文摘要:微生物来源胆汁酸代谢的紊乱与肠道疾病的发生密切相关,涉及炎症性肠病、肠道感染和结直肠癌等。人工智能辅助的分析流程近来使胆汁酸修饰反应的鉴定成为可能,由此发现了新的靶点以及参与肠道疾病发生的机制。本综述梳理了有关微生物酶促通路与胆汁酸修饰及其促发或阻止肠道疾病作用的最新研究。进一步讨论了改变肠道菌群构成与微生物胆汁酸代谢格局、进而影响肠道疾病的机制,以及微生物来源胆汁酸如何调控肠道免疫应答。基于上述进展,提出了通过不同膳食模式重塑肠道菌群与胆汁酸以预防肠道疾病的思路。还讨论了微生物胆汁酸修饰在肠道稳态中基础与转化研究面临的现时难题,并提出推动该领域进展的未来方向。

4肠易激/IBS (1篇)

基础研究 (1篇)

Annual review of physiology IF 20.3 2026-10-14 PMID: 42874001
The brain-gut-microbiome system is an integrated communication network linking the central nervous system, enteric nervous system, immune pathways, and intestinal microbiota. Increasing evidence indicates that dysregulation of this bidirectional signaling system contributes to both gastrointestinal and psychiatric disorders. Irritable bowel syndrome (IBS), a disorder of gut-brain interaction, and major depressive disorder (MDD) frequently coexist and share multiple biological and environmental risk factors. Advances in microbiome science, neuroimaging, and multi-omics technologies have revealed that microbial metabolites, neuroimmune signaling, and stress-responsive neuroendocrine pathways influence neural circuits regulating mood, visceral perception, and gastrointestinal function. These interconnected mechanisms may explain the high comorbidity between IBS and MDD and suggest that both conditions arise from disturbances across overlapping biological systems. In this review, we synthesize current knowledge of genetic, neurobiological, and potential microbial contributors to IBS and depression, discuss emerging therapeutic approaches targeting the brain-gut-microbiome system, and highlight future directions for developing mechanistically informed treatment strategies.
中文摘要:脑-肠-微生物系统是一个整合性通讯网络,连接中枢神经系统、肠神经系统、免疫通路和肠道微生物群。越来越多证据表明,该双向信号系统失调参与胃肠道和精神疾病。肠易激综合征(IBS)是一种肠-脑相互作用障碍,重性抑郁障碍(MDD)常与其共存,并共享多种生物学和环境风险因素。微生物组科学、神经影像和多组学技术的进展揭示,微生物代谢物、神经免疫信号和应激反应性神经内分泌通路影响调节情绪、内脏感知和胃肠功能的神经环路。这些相互关联的机制可能解释IBS与MDD的高共病率,并提示两种疾病源于重叠生物学系统的紊乱。本综述整合关于IBS和抑郁的遗传、神经生物学及潜在微生物贡献的现有知识,讨论靶向脑-肠-微生物系统的新兴治疗策略,并指出开发以机制为依据的治疗策略的未来方向。

5肝病/肝硬化 (1篇)

基础研究 (1篇)

Nature biotechnology IF 44.5 2026-10-13 PMID: 42870042
Targeted lipid nanoparticles (LNPs) offer a nonviral approach for in vivo cell engineering but efficient programming of natural killer (NK) cells remains underexplored. Here we develop NK cell-targeted LNPs (NtLNPs) using engineered biparatopic NK cell ligands to drive receptor-specific uptake and mRNA delivery. Lead NtLNPs achieve up to ~80% NK cell transfection with minimal off-target effects in mice. Systemic delivery of chimeric antigen receptor (CAR) mRNA using NtLNPs generates CAR NK cells in vivo. CD19-targeted CAR NKs completely deplete circulating B cells in healthy mice and CD3-targeted CAR NKs eliminate nearly all autoreactive T cells in an autoimmune hepatitis model, highlighting a potential advantage over CAR T therapies for T cell-driven disease. In solid tumors, NtLNPs targeting the inhibitory checkpoint NKG2A enhance antitumor efficacy by relieving Qa-1b-mediated immunosuppression. Lastly, we optimized NtLNPs for in vivo engineering of human CAR NK cells, enabling regression of two humanized hematologic malignancy models and establishing NtLNPs as a modular immunotherapy system.
中文摘要:靶向脂质纳米颗粒(LNPs)为体内细胞工程提供了非病毒途径,但高效编程自然杀伤(NK)细胞仍研究不足。利用工程化双旁位NK细胞配体开发NK细胞靶向LNPs(NtLNPs),以驱动受体特异性摄取和mRNA递送。先导NtLNPs在小鼠中实现高达约80%的NK细胞转染,脱靶效应很小。经NtLNPs全身递送嵌合抗原受体(CAR)mRNA可在体内生成CAR NK细胞。靶向CD19的CAR NK细胞在健康小鼠中完全清除循环B细胞,靶向CD3的CAR NK细胞在自身免疫性肝炎模型中清除几乎全部自身反应性T细胞,显示其对T细胞驱动疾病可能优于CAR T疗法。在实体瘤中,靶向抑制性检查点NKG2A的NtLNPs通过缓解Qa-1b介导的免疫抑制增强抗肿瘤疗效。研究还优化NtLNPs用于体内工程化人CAR NK细胞,使两种人源化血液恶性肿瘤模型获得消退,并确立NtLNPs作为一种模块化免疫治疗系统。

6胰腺炎 (1篇)

基础研究 (1篇)

Gastroenterology IF 29.7 2026-10-13 PMID: 42869256
Chronic pancreatitis (CP) is a progressive fibroinflammatory disease with rising global incidence and no curative therapy. Gut dysbiosis has been associated with CP, but its causal contribution to disease pathogenesis remains unclear. We intended to identify specific pathogenic microbial species that promote CP and to delineate the underlying pathogenic mechanisms. Multi-omics analyses were used to identify key microbial signatures in CP patients and mice. Novel pathogenic Escherichia coli strains were isolated and bioengineered for functional studies. In vitro and in vivo assays, along with macrophage-specific knockout mice, adenoviral tools, and pharmacological inhibitors, were employed to dissect host-microbe mechanistic pathways. Therapeutic intervention included administering a screened next-generation probiotic. Metagenomic sequencing identified HtpG-high-expressing E. coli (HHEC) enrichment as a dominant microbial signature in CP patients. Prevention of HHEC adherence and colonization alleviated CP, whereas recolonization with a new patient-derived HHEC strain PS718 exacerbated it. Mechanistically, E. coli-derived HtpG upregulated protein arginine methyltransferase 5 (PRMT5) in pancreatic macrophages. Pharmacological inhibition of PRMT5 or macrophage-specific deletion of PRMT5 mitigated pancreatic fibrosis and CP progression. PRMT5 methylated Krüppel-like factor 4 (KLF4) at residues R387/R389, stabilizing it, which promoted M2 polarization and pancreatic fibrosis. Therapeutic intervention with Akkermansia muciniphila, which is reduced in CP, suppressed HHEC colonization and ameliorated CP. These findings provide novel evidence for a pathogenic HHEC-HtpG-macrophage axis in CP, highlighting the potential of microbiota-targeted therapies for the condition.
中文摘要:慢性胰腺炎(CP)是一种进行性纤维炎症性疾病,全球发病率上升,尚无治愈性疗法。肠道菌群失调与CP相关,但其对疾病发病机制的因果作用仍不清楚。我们旨在识别促进CP的特定致病微生物种类并阐明其潜在致病机制。采用多组学分析识别CP患者和小鼠中的关键微生物特征。分离新型致病性大肠埃希菌菌株并进行生物工程改造用于功能研究。通过体外和体内实验,结合巨噬细胞特异性敲除小鼠、腺病毒工具和药理学抑制剂,剖析宿主-微生物机制通路。治疗干预包括给予筛选出的下一代益生菌。宏基因组测序识别出高表达HtpG的大肠埃希菌(HHEC)富集是CP患者中的主要微生物特征。阻止HHEC黏附和定植可减轻CP,而用新的患者来源HHEC菌株PS718重新定植则加重CP。机制上,大肠埃希菌来源的HtpG上调胰腺巨噬细胞中的蛋白精氨酸甲基转移酶5(PRMT5)。药理学抑制PRMT5或巨噬细胞特异性缺失PRMT5可减轻胰腺纤维化和CP进展。PRMT5在R387/R389位点甲基化Krüppel样因子4(KLF4),使其稳定,从而促进M2极化和胰腺纤维化。用在CP中减少的嗜黏蛋白阿克曼菌进行治疗干预,可抑制HHEC定植并改善CP。这些发现为CP中的致病性HHEC-HtpG-巨噬细胞轴提供了新证据,凸显了微生物群靶向治疗该疾病的潜力。

7慢性肝病 (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-10-13 PMID: 42862908
Chronic liver disease is an increasingly prevalent and heterogeneous syndrome with important consequences for cardiovascular function. As the global burdens of chronic liver disease and cirrhosis continue to rise, cardiovascular disease has emerged as a major driver of overall morbidity and mortality in affected patients. Despite the growing recognition of the intersectionality between hepatology and cardiology care clinically, cardiovascular disease risk among patients with liver disease is underrecognized. This state-of-the-art review summarizes the current understanding of the bidirectional interactions between the liver and the cardiovascular system. Shared mechanisms-including inflammation, endothelial injury, and neurohormonal overactivation-that contribute to the development of adverse myocardial remodeling, atherosclerotic cardiovascular disease, heart failure, arrhythmias, pulmonary vascular syndromes, and cirrhosis-associated cardiovascular syndromes are reviewed. A specific focus is placed on metabolic dysfunction-associated steatotic liver disease, the most common form of chronic liver disease, while highlighting the distinct cardiovascular manifestations associated with other types of chronic liver disease. These include alcohol-associated liver disease and infiltrative diseases that affect the liver and heart with cardiovascular implications across the spectrum from early stages of liver disease through cirrhosis. We discuss practical approaches to detecting liver disease, including the assessment of liver fibrosis noninvasively in individuals at risk. We discuss the approach to assessing cardiovascular risk through cardiac imaging, biomarkers, and cardiac functional testing once chronic liver disease is detected. Management considerations for commonly encountered cardiovascular conditions and a critical appraisal of the evolving evidence supporting cardiometabolic therapies in patients with chronic liver disease are discussed to underscore potential cardiovascular and liver benefits. Critical evidence gaps and future research priorities are identified, including the development and evaluation of liver-informed cardiovascular risk models, incorporation of cardiovascular end points into liver disease trials, and implementation of integrated cardiohepatometabolic care pathways. Improved recognition of chronic liver disease and related cardiovascular disease risk represents a major opportunity to facilitate earlier disease detection, enhance risk stratification, and improve outcomes across the spectrum of chronic liver disease.
中文摘要:慢性肝病是一种患病率不断上升的异质性综合征,对心血管功能有重要影响。随着全球慢性肝病和肝硬化负担持续增加,心血管疾病已成为这类患者总体疾病负担和死亡的主要驱动因素。临床对肝病与心脏病学诊疗交叉的认识不断增强,但肝病患者的心血管疾病风险仍被低估。该前沿综述总结当前对肝脏与心血管系统双向相互作用的理解,回顾炎症、内皮损伤和神经激素过度激活等共同机制如何促成不良心肌重构、动脉粥样硬化性心血管疾病、心力衰竭、心律失常、肺血管综合征和肝硬化相关心血管综合征。重点讨论代谢功能障碍相关脂肪性肝病这一最常见的慢性肝病类型,并强调其他慢性肝病相关的心血管表现,包括酒精相关性肝病以及同时累及肝脏和心脏的浸润性疾病,其心血管影响贯穿肝病早期至肝硬化阶段。讨论检测肝病的实用方法,包括对高危个体进行无创肝纤维化评估。讨论在发现慢性肝病后通过心脏影像、生物标志物和心脏功能检查评估心血管风险的路径。讨论常见心血管情况的处理考虑,并批判性评价支持心代谢治疗用于慢性肝病患者的不断演变的证据,以突出其潜在心血管和肝脏获益。指出关键证据缺口和未来研究重点,包括开发与评价结合肝脏信息的心血管风险模型、将心血管终点纳入肝病试验,以及实施整合心-肝-代谢的诊疗路径。提高对慢性肝病及相关心血管疾病风险的认识,为促进更早期疾病发现、改善风险分层和改善慢性肝病全程结局提供了重要机会。

8消化道早癌筛查 (1篇)

临床研究 (1篇)

Endoscopy IF 11.8 2026-10-13 PMID: 42664999
Post-endoscopy upper gastrointestinal cancer (PEUGIC) is an emerging quality metric, but varying definitions complicate benchmarking. We characterized PEUGIC rates and outcomes by anatomic site and coded high-risk condition (HRC) status in a large US cohort. This was a retrospective cancer-first cohort study of 14 814 patients with upper gastrointestinal cancer (UGIC) from a multicenter database (2016-2024). Index endoscopy-detected UGIC was diagnosed within 6 months of esophagogastroduodenoscopy. PEUGIC was defined as UGIC diagnosed 6-36 months after a nondiagnostic esophagogastroduodenoscopy. The primary outcome was PEUGIC rate by cancer type and HRC status. Secondary outcomes included 3-year overall survival. The overall PEUGIC rate was 9.4% (esophageal cancer 9.6%, gastric cancer 8.6%, duodenal cancer 10.7%). Rates were higher with HRC (18.2%) than without HRC (5.0%; P < 0.001). PEUGIC rate without HRC plateaued (4.0%-5.1% in 2022-2024), while PEUGIC rate with HRC for esophageal cancer (16.8%) and gastric cancer (14.4%) decreased over time. In exploratory analysis, PEUGIC was associated with better survival vs. index endoscopy-detected UGIC for esophageal cancer (adjusted hazard ratio [aHR] 0.82, 95%CI 0.67-0.99) and gastric cancer (aHR 0.77, 0.62-0.96), and PEUGIC with HRC was associated with lower mortality vs. PEUGIC without HRC for esophageal cancer (aHR 0.51, 0.36-0.74) and gastric cancer (aHR 0.50, 0.34-0.73). 1 in 10 UGIC patients had a prior nondiagnostic endoscopy within 3 years. PEUGIC rates varied by anatomic site and HRC status, suggesting site- and HRC-stratified benchmarks may better capture endoscopic performance than aggregate metrics.
中文摘要:内镜后上消化道癌(PEUGIC)正逐渐成为一项新的质量指标,但定义不一致使基准比较变得复杂。本研究在美国一个大型队列中,按解剖部位和高危疾病编码状态(HRC)描述了PEUGIC的发生率与结局。这是一项以癌症为起点的回顾性队列研究,纳入多中心数据库(2016—2024年)中14814例上消化道癌患者。索引内镜检出上消化道癌指食管胃十二指肠镜检查(EGD)后6个月内确诊;PEUGIC指一次未获诊断的EGD后6至36个月确诊的上消化道癌。主要结局为按癌种和HRC状态分类的PEUGIC发生率,次要结局包括3年总生存。总体PEUGIC发生率为9.4%(食管癌9.6%、胃癌8.6%、十二指肠癌10.7%)。有HRC者为18.2%,高于无HRC者的5.0%(P<0.001)。无HRC的PEUGIC发生率趋于平稳(2022—2024年为4.0%—5.1%),而有HRC的食管癌(16.8%)与胃癌(14.4%)PEUGIC发生率随时间下降。探索性分析中,食管癌(校正风险比aHR 0.82,95%CI 0.67—0.99)与胃癌(aHR 0.77,0.62—0.96)的PEUGIC相比索引内镜检出者生存更好;有HRC的PEUGIC相比无HRC者死亡风险更低,食管癌aHR 0.51(0.36—0.74),胃癌aHR 0.50(0.34—0.73)。约每10例上消化道癌患者中有1例在3年内曾接受未获诊断的内镜检查。PEUGIC发生率随解剖部位与HRC状态而异,提示按部位与HRC分层的基准可能比汇总指标更能反映内镜表现。